In a letter to the editor published in The New England Journal of Medicine (2013;268:194), Marc B. Garnick, MD, of Beth Israel Deaconess Medical Center in Boston, took issue with the naming of new drugs for treating patients with metastatic prostate cancer.
He wrote that the “proclivity to include the letters X and Z in the marketed trade name names will undoubtedly lead to confusion both by the physician prescribing and the pharmacy dispensing these agents.”
These drugs include Zometa, Xgeva, Zytiga, and Xtandi. Renal & Urology News would like to know if urologists agree with Dr. Garnick, so please answer the following poll question.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.
